{"id":4922,"date":"2023-11-09T08:29:19","date_gmt":"2023-11-09T08:29:19","guid":{"rendered":"https:\/\/ctm.u-bourgogne.fr\/?p=4922"},"modified":"2024-01-29T08:43:40","modified_gmt":"2024-01-29T08:43:40","slug":"a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer","status":"publish","type":"post","link":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/","title":{"rendered":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. <a href=\"https:\/\/bmccancer.biomedcentral.com\/\" title=\"\">BMC Cancer<\/a>. 2023 Nov 9;23(1):1080. doi: <a href=\"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11534-6\" title=\"\">10.1186\/s12885-023-11534-6<\/a>. PMID: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37946136\/\" title=\"\">37946136<\/a>; PMCID: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10633948\/\" title=\"\">PMC10633948<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Trial registration:<\/strong> This study is registered on ClinicalTrials.gov: <a href=\"http:\/\/clinicaltrials.gov\/show\/NCT05259319\">NCT05259319<\/a>, since February 28th, 2022.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"715\" height=\"725\" src=\"https:\/\/ctm.u-bourgogne.fr\/wp-content\/uploads\/2024\/01\/image-1.png\" alt=\"\" class=\"wp-image-4923\" srcset=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/image-1.png 715w, https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/image-1-296x300.png 296w\" sizes=\"(max-width: 715px) 100vw, 715px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I &#8230; <a title=\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\" class=\"read-more\" href=\"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/\" aria-label=\"En savoir plus sur A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\">Lire la suite<\/a><\/p>\n","protected":false},"author":23,"featured_media":4926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[3],"tags":[],"class_list":["post-4922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Francois Hermetet\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"CTM -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM\" \/>\n\t\t<meta property=\"og:description\" content=\"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-11-09T08:29:19+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-01-29T08:43:40+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#blogposting\",\"name\":\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM\",\"headline\":\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\",\"author\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/12885_2023_11534_Figa_HTML.webp\",\"width\":2008,\"height\":1364,\"caption\":\"Rationale: SBRT induces immunogenic cell death, which promotes TAAs and\\\/or TNAs uptake by DCs. Then DCs migrate into the DLN in order to prime naive T cells. After activation in the DLN, CD8 T cells join irradiated and non-irradiated lesions to perform their anti-tumor immune function. CD8 T cell: CD8 T lymphocyte; DC: dendritic cell; DLN: draining lymph node; PD-L1: programmed death-ligand 1; PVR: poliovirus receptor; SBRT: stereotactic body radiation therapy; TAA: tumor-associated antigen; TNA: tumor neoantigen; TIGIT: T cell immunoreceptor with Ig and ITIM domains\"},\"datePublished\":\"2023-11-09T08:29:19+00:00\",\"dateModified\":\"2024-01-29T08:43:40+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#webpage\"},\"articleSection\":\"Publication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ctm.ube.fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"name\":\"Publication\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"position\":2,\"name\":\"Publication\",\"item\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#listItem\",\"name\":\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#listItem\",\"position\":3,\"name\":\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/category\\\/publication\\\/#listItem\",\"name\":\"Publication\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\",\"name\":\"CTM\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CTM-LOGO-350_70.jpg\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#organizationLogo\",\"width\":350,\"height\":70},\"image\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/\",\"name\":\"Francois Hermetet\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d660d5bc961dd55ff293be175456994b87cd31966fb5a061dfb4ad2af59b627?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Francois Hermetet\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#webpage\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/\",\"name\":\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM\",\"description\":\"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/author\\\/fr3763he\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/12885_2023_11534_Figa_HTML.webp\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#mainImage\",\"width\":2008,\"height\":1364,\"caption\":\"Rationale: SBRT induces immunogenic cell death, which promotes TAAs and\\\/or TNAs uptake by DCs. Then DCs migrate into the DLN in order to prime naive T cells. After activation in the DLN, CD8 T cells join irradiated and non-irradiated lesions to perform their anti-tumor immune function. CD8 T cell: CD8 T lymphocyte; DC: dendritic cell; DLN: draining lymph node; PD-L1: programmed death-ligand 1; PVR: poliovirus receptor; SBRT: stereotactic body radiation therapy; TAA: tumor-associated antigen; TNA: tumor neoantigen; TIGIT: T cell immunoreceptor with Ig and ITIM domains\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/index.php\\\/2023\\\/11\\\/09\\\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\\\/#mainImage\"},\"datePublished\":\"2023-11-09T08:29:19+00:00\",\"dateModified\":\"2024-01-29T08:43:40+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#website\",\"url\":\"https:\\\/\\\/ctm.ube.fr\\\/\",\"name\":\"CTM\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/ctm.ube.fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM","description":"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I","canonical_url":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#blogposting","name":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM","headline":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer","author":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"publisher":{"@id":"https:\/\/ctm.ube.fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2023\/11\/12885_2023_11534_Figa_HTML.webp","width":2008,"height":1364,"caption":"Rationale: SBRT induces immunogenic cell death, which promotes TAAs and\/or TNAs uptake by DCs. Then DCs migrate into the DLN in order to prime naive T cells. After activation in the DLN, CD8 T cells join irradiated and non-irradiated lesions to perform their anti-tumor immune function. CD8 T cell: CD8 T lymphocyte; DC: dendritic cell; DLN: draining lymph node; PD-L1: programmed death-ligand 1; PVR: poliovirus receptor; SBRT: stereotactic body radiation therapy; TAA: tumor-associated antigen; TNA: tumor neoantigen; TIGIT: T cell immunoreceptor with Ig and ITIM domains"},"datePublished":"2023-11-09T08:29:19+00:00","dateModified":"2024-01-29T08:43:40+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#webpage"},"isPartOf":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#webpage"},"articleSection":"Publication"},{"@type":"BreadcrumbList","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr#listItem","position":1,"name":"Home","item":"https:\/\/ctm.ube.fr","nextItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","name":"Publication"}},{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","position":2,"name":"Publication","item":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/","nextItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#listItem","name":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer"},"previousItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#listItem","position":3,"name":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer","previousItem":{"@type":"ListItem","@id":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/#listItem","name":"Publication"}}]},{"@type":"Organization","@id":"https:\/\/ctm.ube.fr\/#organization","name":"CTM","url":"https:\/\/ctm.ube.fr\/","logo":{"@type":"ImageObject","url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#organizationLogo","width":350,"height":70},"image":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author","url":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/","name":"Francois Hermetet","image":{"@type":"ImageObject","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/8d660d5bc961dd55ff293be175456994b87cd31966fb5a061dfb4ad2af59b627?s=96&d=mm&r=g","width":96,"height":96,"caption":"Francois Hermetet"}},{"@type":"WebPage","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#webpage","url":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/","name":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM","description":"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/ctm.ube.fr\/#website"},"breadcrumb":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#breadcrumblist"},"author":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"creator":{"@id":"https:\/\/ctm.ube.fr\/index.php\/author\/fr3763he\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2023\/11\/12885_2023_11534_Figa_HTML.webp","@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#mainImage","width":2008,"height":1364,"caption":"Rationale: SBRT induces immunogenic cell death, which promotes TAAs and\/or TNAs uptake by DCs. Then DCs migrate into the DLN in order to prime naive T cells. After activation in the DLN, CD8 T cells join irradiated and non-irradiated lesions to perform their anti-tumor immune function. CD8 T cell: CD8 T lymphocyte; DC: dendritic cell; DLN: draining lymph node; PD-L1: programmed death-ligand 1; PVR: poliovirus receptor; SBRT: stereotactic body radiation therapy; TAA: tumor-associated antigen; TNA: tumor neoantigen; TIGIT: T cell immunoreceptor with Ig and ITIM domains"},"primaryImageOfPage":{"@id":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/#mainImage"},"datePublished":"2023-11-09T08:29:19+00:00","dateModified":"2024-01-29T08:43:40+00:00"},{"@type":"WebSite","@id":"https:\/\/ctm.ube.fr\/#website","url":"https:\/\/ctm.ube.fr\/","name":"CTM","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/ctm.ube.fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"CTM -","og:type":"article","og:title":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM","og:description":"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I","og:url":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/","og:image":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","og:image:secure_url":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg","article:published_time":"2023-11-09T08:29:19+00:00","article:modified_time":"2024-01-29T08:43:40+00:00","twitter:card":"summary_large_image","twitter:title":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer - CTM","twitter:description":"Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I","twitter:image":"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/02\/CTM-LOGO-350_70.jpg"},"aioseo_meta_data":{"post_id":"4922","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-01-29 08:36:49","updated":"2025-08-13 19:15:51","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/ctm.ube.fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/\" title=\"Publication\">Publication<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tA phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/ctm.ube.fr"},{"label":"Publication","link":"https:\/\/ctm.ube.fr\/index.php\/category\/publication\/"},{"label":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer","link":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/"}],"publishpress_future_action":{"enabled":false,"date":"2026-07-18 19:39:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/comments?post=4922"}],"version-history":[{"count":1,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922\/revisions"}],"predecessor-version":[{"id":4924,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922\/revisions\/4924"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/media\/4926"}],"wp:attachment":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/media?parent=4922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/categories?post=4922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/tags?post=4922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}